Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

PROSCA/BLADDR 2022 | IsoPSA: blood-based assay for improved detection of prostate cancer

Eric Klein, MD, Glickman Urology & Kidney Institute, Cleveland, OH, discusses IsoPSA, a blood-based test that assesses prostate cancer risk by detecting cancer-specific structural isoforms of prostate specific antigen (PSA). IsoPSA is more accurate than PSA at predicting likelihood of prostate cancer, and in a prospective study, reduced incidence of unnecessary biopsies by 50%. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR 2022) in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.